SynBio8: Targeted Debugging: Programming Cells to Eradicate Cancer (v1.1)

There were about 10 million deaths worldwide due to cancer in 2020, accounting for roughly one in six deaths globally. Cancer is a particularly prominent cause of death in wealthier nations, where other traditional causes of mortality—such as infectious diseases and maternal risks—have been significantly reduced. Today, the rise in global cancer deaths is primarily driven by two demographic shifts: population growth and population aging.

While the cornerstone conventional treatments have long been chemotherapy, radiation therapy, and bone marrow transplants, synthetic biology (SynBio) has begun to offer entirely new paradigms for tackling this scourge. Chief among these is the rapidly advancing field of immunotherapy.

CAR T-Cell Therapy: Reprogramming Cellular Soldiers

Synthetic biology can be used to genetically reprogram a patient's own immune cells to precisely target and destroy malignancies. In 2017, the FDA approved the first two such therapies for blood cancers.

In CAR T-cell therapy (chimeric antigen receptor T-cell therapy), immune T-cells are harvested from the patient's blood. In the laboratory, scientists use SynBio techniques to insert a synthetic gene encoding a custom receptor (the CAR) onto the surface of these cells. After millions of these enhanced cells are grown, they are infused back into the patient. The engineered CAR T-cells hunt down the cancer cells, bind to specific surface proteins, and destroy them.

The clinical results of this treatment have been extraordinarily promising. Furthermore, ongoing research is modifying these cellular logic gates so they can differentiate between healthy tissue and malignant cells, allowing scientists to safely apply this therapy to complex solid tumors, such as glioblastoma (an aggressive form of brain cancer).

Virotherapy: Designer Oncolytic Viruses

Virotherapy is another fascinating branch of immunotherapy. Clinicians have known for over a century that accidental viral infections can occasionally influence cancer dynamics and trigger temporary remissions. Armed with modern synthetic biology, scientists can now craft "designer viruses" to safely turn this phenomenon into a targeted weapon.

In oncolytic biotherapy, engineered viruses are constructed to selectively infect and replicate inside cancer cells and tumors. Once a virus enters a cancer cell, it hijacks the machinery to replicate itself until the host cancer cell bursts (lyses). This rupture destroys the cancer cell directly and floods the surrounding tumor microenvironment with debris and viral chemical markers. This effectively "paints" the tumor, alerting the body's native T-cells to a massive threat and triggering a systemic immune attack.

In 2015, a modified herpes simplex virus became the first oncolytic viral therapy approved by the FDA for clinical use. The frontier of this research relies on SynBio to perfectly balance the virus's ability to destroy cancer without triggering an immune response that clears the virus from the body too early.

The Renaissance of Bacteria-Based Therapies

The concept of using bacteria to treat cancer is actually an old medical idea that is currently experiencing a massive, SynBio-driven renaissance. Our bodies are naturally home to trillions of bacteria, particularly within the gut microbiome. Over the past decade, bacteria-based cancer immunotherapy has attracted intense academic focus due to its unique mechanisms and its potent ability to trigger host anti-tumor immunity.

One remarkable, inherent advantage of certain bacteria is their capability to autonomously navigate toward tumors and preferentially colonize the hypoxic (low-oxygen) core areas of a tumor mass. Bacteria living inside a tumor can directly disrupt cancer cells from the inside out.

By applying synthetic biology, scientists can engineer safe, non-pathogenic strains of bacteria to enhance this localized destruction. These engineered microbes can act as microscopic factories inside the tumor, producing and releasing localized therapeutic drugs or signaling molecules directly where they are needed most, minimizing side effects throughout the rest of the body. Several of these living therapies have successfully entered human clinical trials.

mRNA Vaccine Hydrogels: Targeted Painting

Vaccine therapy represents another cutting-edge technique being developed to train the body to reject tumors. A notable 2021 study by scientists in China showcases how SynBio can innovate delivery mechanisms for these therapies.

In this study, researchers created a specialized hydrogel infused with tumor-targeting mRNA packed into lipid nanoparticles, which was then injected directly next to melanoma tumors in mice. The unique property of the hydrogel allowed for a highly sustained, slow release of the mRNA nanoparticles over a 30-day period.

As the mRNA enters nearby cancer cells, it instructs them to produce a specific, highly visible foreign protein on their surface. By effectively painting a massive target on the tumor cells, the treatment allows local T-cells to easily identify, swarm, and eliminate the cancer.

The relentless pace of research in these various immunotherapies provides immense hope, showing that rewriting the code of living systems may ultimately allow us to outsmart cancer.

How does this version read to you? If you'd like, we can easily dive deeper into any of these pillars—for instance, mentioning how the bacterial therapies handle safety (like engineered "kill switches"), or providing a brief historical nod to William Coley (the 19th-century doctor who first tried bacteria therapy) to give the renaissance point some historical context.

Want to Read on?

 Go to Main Hub